Wait, we have a special offer for you! ✋

Get your exclusive discount now

YES, get the discount! No, I'd pay the full price
Global Neurological Disorder Drugs Market Report 2025

Neurological Disorder Drugs Global Market Report 2025 – By Drug Class (Cholinesterase Inhibitors, N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, Antiepileptic, Antipsychotic And Antidepressant, Other Drugs Classes), By Indication (Epilepsy, Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Cerebrovascular Disease, Other Indications), By Route Of Administration (Oral, Parenteral, Other Routes Of Administration), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels), By End-Users (Hospitals, Specialty Clinics, Homecare, Other End Users) – Market Size, Trends, And Global Forecast 2025-2034

Neurological Disorder Drugs Global Market Report 2025

Report Price : $4490.00 | Pages : 175 | Published : January 2025 | Delivery Time: 2-3 business days | Format : pdf

Purchase Options
Request a Sample
Request For Discount
Customise Your Report
Item added to cart!
Request For Proposal
Request For Regional Data
FAQs

Need assistance or more information before the purchase?

Enquire Before Buying
Neurological Disorder Drugs Global Market Report 2025

Proud Members Of

checkslacipN checkaoirsN checkscipN
Description Table Of Contents Tables & Figures Market Insights Related Reports

Neurological Disorder Drugs Market Definition

Neurological disorder drugs refer to medications used to treat disorders of the nervous system. These disorders can affect the brain, spinal cord, and nerves throughout the body. The drugs aim to manage symptoms, slow the progression of the disorder, and improve the quality of life for individuals affected.

The main types of drug classes in neurological disorders are cholinesterase inhibitors, N-Methyl-D-Aspartate (NMDA) receptor antagonists, antiepileptics, antipsychotics, antidepressants, and others. Cholinesterase inhibitors are medications that prevent the breakdown of acetylcholine, a neurotransmitter involved in memory and cognitive function. Which can be used for various indications such as epilepsy, alzheimer’s disease, parkinson’s disease, multiple sclerosis, cerebrovascular disease, and others, through various routes of administration, including oral, parenteral, and others. And these can be distributed through various channels, including hospital pharmacies, retail pharmacies, online pharmacies, and others, and end users are hospitals, specialty clinics, home care, and others.

Neurological Disorder Drugs Market Segmentation

The neurological disorder drugs market covered in this report is segmented –

1) By Drug Class: Cholinesterase Inhibitors, N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, Antiepileptic, Antipsychotic And Antidepressant, Other Drugs Classes

2) By Indication: Epilepsy, Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Cerebrovascular Disease, Other Indications

3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

5) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End Users

Subsegtments:

1) By Cholinesterase Inhibitors: Donepezil, Rivastigmine, Galantamine

2) By N-Methyl-D-Aspartate (NMDA) Receptor Antagonists: Memantine, Other NMDA Receptor Antagonists

3) By Antiepileptic: Sodium Channel Blockers, GABA Enhancers, Glutamate Modulators, Other Antiepileptics

4) By Antipsychotic and Antidepressant: Risperidone, olanzapine, SSRIs, SNRIs, Tricyclic

5) By Other Drug Classes: Dopaminergic Drugs, Alpha-2 Agonists, Immunomodulators, Other Neurological Disorder Medications

Neurological Disorder Drugs Market Size and growth rate 2025 to 2029: Graph

Neurological Disorder Drugs Market Size 2025 And Growth Rate

The neurological disorder drugs market size has grown strongly in recent years. It will grow from $84.6 billion in 2024 to $90.09 billion in 2025 at a compound annual growth rate (CAGR) of 6.5%. The growth in the historic period can be attributed to increasing animal testing and obtaining promising results, an increase in therapeutic treatments, the growth of neurological problems, government initiatives, and a growth in healthcare expenditure.

Neurological Disorder Drugs Market Growth Forecast

The neurological disorder drugs market size is expected to see strong growth in the next few years. It will grow to $114.65 billion in 2029 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to expanding therapeutic options and personalized therapies, a growing focus on disease-modifying treatments, the expanding use of digital biomarkers, and the increasing prevalence of neurological diseases. Major trends in the forecast period include advancements in drug design, advancements in neuroimaging, advancements in genetic research, collaborations and licensing agreements, and the emergence of regenerative medicine.

Book your 30 minutes free consultation with our research experts

Contact Us

Neurological Disorder Drugs Market Driver: Rising Neurological Disorders Drive Growth In Drugs Market

The increasing prevalence of neurological diseases is expected to propel the growth of the neurological disorder drugs market going forward. Neurological disorders refer to the conditions affecting the brain, spinal cord, and nerves caused by structural, biochemical, or electrical abnormalities, leading to various symptoms. The increase in neurological diseases is attributed to the aging global population and greater exposure to environmental, metabolic, and lifestyle risk factors. Neurological disorder drugs play a critical role in managing these complex conditions, offering relief from symptoms, slowing disease progression, and improving long-term outcomes for patients. For instance, in September 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, IT is projected that the number of people living with dementia in Australia will more than double between 2023 and 2058, increasing from approximately 411,100 in 2023 to 849,300 by 2058, with around 315,500 men and 533,800 women affected. Therefore, the increasing prevalence of neurological disease is driving the growth of the neurological disorder drugs market.

Global Neurological Disorder Drugs Market Major Players

Major companies operating in the neurological disorder drugs market are F. Hoffmann-La Roche Ltd, Bayer AG, Sanofi S.A, AstraZeneca PLC, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company Pvt Ltd, Amgen Inc, Boehringer Ingelheim GmbH, Novo Nordisk A/S, Merck KGaA, Teva Pharmaceutical Industries Ltd, Otsuka America Pharmaceutical Inc, Biogen Inc, Bausch Health Companies Inc, Alexion Pharmaceuticals Inc., UCB S.A., Eisai Co Ltd, Cipla Inc, BioMarin Pharmaceutical Inc., Biocon Ltd, Acorda Therapeutics Inc.

Global Neurological Disorder Drugs Market Trend: Innovative Approaches In Neurological Disorder Drugs Advancing Treatment For Multiple Sclerosis

Major companies operating in the neurological disorder drugs market are focusing on developing innovative Ocrelizumab drug therapies to enhance treatment efficacy, improve patient outcomes, and expand therapeutic options for individuals with multiple sclerosis. Ocrelizumab is a humanized monoclonal antibody used as a therapeutic drug in the treatment of multiple sclerosis (MS), a type of neurological disorder. For instance, in February 2024, Roche Holding AG, a Switzerland-based pharmaceutical company, launched Ocrevus (Ocrelizumab), a new disease-modifying therapy (DMT) drug for the treatment of multiple sclerosis in India. Ocrevus is the first and only approved DMT for both relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS), based on over 10 years of clinical and real-world data. It is a monoclonal antibody that targets CD20-positive B cells, which are believed to play a role in the autoimmune attack on the central nervous system in multiple sclerosis (MS). Ocrevus is used to treat both relapsing-remitting MS (RRMS) and primary progressive MS (PPMS), making IT the first drug approved for both forms of the disease. It is administered intravenously, typically every six months, and has shown efficacy in reducing disease activity and disability progression in clinical trials.

Neurological Disorder Drugs Market Merger And Acquisition: Pfizer's Acquisition Of Biohaven Pharmaceuticals Enhancing Global Leadership In Migraine Treatments

In October 2022, Pfizer Inc., a US-based pharmaceutical company, acquired Biohaven Pharmaceuticals for $11.6 billion. Through this acquisition, Pfizer aims to strengthen its innovative internal medicine pipeline and global reach in migraine treatments by gaining access to Biohaven's breakthrough calcitonin gene-related peptide portfolio, including the approved NURTEC ODT and pipeline assets such as Zavegepant. Pfizer aims to deliver these innovative therapies to over 1 billion people worldwide affected by migraine. Biohaven Pharmaceutical is a US-based, clinical-stage biopharmaceutical company that offers a range of neurological and neuropsychiatric disorder drugs.

Regional Outlook For The Global Neurological Disorder Drugs Market

North America was the largest region in the neurological disorder drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurological disorder drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the neurological disorder drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Neurological Disorder Drugs Market?

The neurological disorder drugs market consists of sales of antiepileptic drugs, dopaminergic agents, cholinesterase inhibitors, immunomodulatory drugs, and antipsychotic drugs. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Neurological Disorder Drugs Industry?

The neurological disorder drugs market research report is one of a series of new reports from The Business Research Company that provides neurological disorder drugs market statistics, including neurological disorder drugs industry global market size, regional shares, competitors with a neurological disorder drugs market share, detailed neurological disorder drugs market segments, market trends and opportunities, and any further data you may need to thrive in the neurological disorder drugs industry. This neurological disorder drugs market research report delivers a complete perspective on everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Neurological Disorder Drugs Market Report Forecast Analysis
Report AttributeDetails
Market Size Value In 2025 $90.09 billion
Revenue Forecast In 2034 $114.65 billion
Growth Rate CAGR of 6.2% from 2025 to 2034
Base Year For Estimation 2024
Actual Estimates/Historical Data 2019-2024
Forecast Period 2025 - 2029 - 2034
Market Representation Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered 1) By Drug Class: Cholinesterase Inhibitors, N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, Antiepileptic, Antipsychotic And Antidepressant, Other Drugs Classes
2) By Indication: Epilepsy, Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Cerebrovascular Disease, Other Indications
3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels
5) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End Users Subsegtments: 1) By Cholinesterase Inhibitors: Donepezil, Rivastigmine, Galantamine
2) By N-Methyl-D-Aspartate (NMDA) Receptor Antagonists: Memantine, Other NMDA Receptor Antagonists
3) By Antiepileptic: Sodium Channel Blockers, GABA Enhancers, Glutamate Modulators, Other Antiepileptics
4) By Antipsychotic and Antidepressant: Risperidone, Olanzapine, SSRIs, SNRIs, Tricyclic
5) By Other Drug Classes: Dopaminergic Drugs, Alpha-2 Agonists, Immunomodulators, Other Neurological Disorder Medications
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled F. Hoffmann-La Roche Ltd, Bayer AG, Sanofi S.A, AstraZeneca PLC, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company Pvt Ltd, Amgen Inc, Boehringer Ingelheim GmbH, Novo Nordisk A/S, Merck KGaA, Teva Pharmaceutical Industries Ltd, Otsuka America Pharmaceutical Inc, Biogen Inc, Bausch Health Companies Inc, Alexion Pharmaceuticals Inc., UCB S.A., Eisai Co Ltd, Cipla Inc, BioMarin Pharmaceutical Inc., Biocon Ltd, Acorda Therapeutics Inc.
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

    Table Of Contents

    1. Executive Summary

    2. Neurological Disorder Drugs Market Characteristics

    3. Neurological Disorder Drugs Market Trends And Strategies

    4. Neurological Disorder Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

    5. Global Neurological Disorder Drugs Growth Analysis And Strategic Analysis Framework

    5.1. Global Neurological Disorder Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

    5.2. Analysis Of End Use Industries

    5.3. Global Neurological Disorder Drugs Market Growth Rate Analysis

    5.4. Global Neurological Disorder Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

    5.5. Global Neurological Disorder Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

    5.6. Global Neurological Disorder Drugs Total Addressable Market (TAM)

    6. Neurological Disorder Drugs Market Segmentation

    6.1. Global Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Cholinesterase Inhibitors

    N-Methyl-D-Aspartate (NMDA) Receptor Antagonists

    Antiepileptic

    Antipsychotic And Antidepressant

    Other Drugs Classes

    6.2. Global Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Epilepsy

    Alzheimer’s Disease

    Parkinson’s Disease

    Multiple Sclerosis

    Cerebrovascular Disease

    Other Indications

    6.3. Global Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Oral

    Parenteral

    Other Routes Of Administration

    6.4. Global Neurological Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Hospital Pharmacy

    Retail Pharmacy

    Online Pharmacy

    Other Distribution Channels

    6.5. Global Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Hospitals

    Specialty Clinics

    Homecare

    Other End Users

    6.6. Global Neurological Disorder Drugs Market, Sub-Segmentation Of Cholinesterase Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Donepezil

    Rivastigmine

    Galantamine

    6.7. Global Neurological Disorder Drugs Market, Sub-Segmentation Of N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Memantine

    Other NMDA Receptor Antagonists

    6.8. Global Neurological Disorder Drugs Market, Sub-Segmentation Of Antiepileptic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Sodium Channel Blockers

    GABA Enhancers

    Glutamate Modulators

    Other Antiepileptics

    6.9. Global Neurological Disorder Drugs Market, Sub-Segmentation Of Antipsychotic and Antidepressant, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Risperidone

    Olanzapine

    SSRIs

    SNRIs

    Tricyclic

    6.10. Global Neurological Disorder Drugs Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Dopaminergic Drugs

    Alpha-2 Agonists

    Immunomodulators

    Other Neurological Disorder Medications

    7. Neurological Disorder Drugs Market Regional And Country Analysis

    7.1. Global Neurological Disorder Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    7.2. Global Neurological Disorder Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    8. Asia-Pacific Neurological Disorder Drugs Market

    8.1. Asia-Pacific Neurological Disorder Drugs Market Overview

    Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    8.3. Asia-Pacific Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    8.4. Asia-Pacific Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    9. China Neurological Disorder Drugs Market

    9.1. China Neurological Disorder Drugs Market Overview

    9.2. China Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

    9.3. China Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

    9.4. China Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

    10. India Neurological Disorder Drugs Market

    10.1. India Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    10.2. India Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    10.3. India Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    11. Japan Neurological Disorder Drugs Market

    11.1. Japan Neurological Disorder Drugs Market Overview

    11.2. Japan Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    11.3. Japan Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    11.4. Japan Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    12. Australia Neurological Disorder Drugs Market

    12.1. Australia Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    12.2. Australia Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    12.3. Australia Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    13. Indonesia Neurological Disorder Drugs Market

    13.1. Indonesia Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    13.2. Indonesia Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    13.3. Indonesia Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    14. South Korea Neurological Disorder Drugs Market

    14.1. South Korea Neurological Disorder Drugs Market Overview

    14.2. South Korea Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    14.3. South Korea Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    14.4. South Korea Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    15. Western Europe Neurological Disorder Drugs Market

    15.1. Western Europe Neurological Disorder Drugs Market Overview

    15.2. Western Europe Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    15.3. Western Europe Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    15.4. Western Europe Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    16. UK Neurological Disorder Drugs Market

    16.1. UK Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    16.2. UK Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    16.3. UK Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    17. Germany Neurological Disorder Drugs Market

    17.1. Germany Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    17.2. Germany Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    17.3. Germany Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    18. France Neurological Disorder Drugs Market

    18.1. France Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    18.2. France Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    18.3. France Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    19. Italy Neurological Disorder Drugs Market

    19.1. Italy Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    19.2. Italy Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    19.3. Italy Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    20. Spain Neurological Disorder Drugs Market

    20.1. Spain Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    20.2. Spain Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    20.3. Spain Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    21. Eastern Europe Neurological Disorder Drugs Market

    21.1. Eastern Europe Neurological Disorder Drugs Market Overview

    21.2. Eastern Europe Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    21.3. Eastern Europe Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    21.4. Eastern Europe Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    22. Russia Neurological Disorder Drugs Market

    22.1. Russia Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    22.2. Russia Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    22.3. Russia Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    23. North America Neurological Disorder Drugs Market

    23.1. North America Neurological Disorder Drugs Market Overview

    23.2. North America Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    23.3. North America Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    23.4. North America Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    24. USA Neurological Disorder Drugs Market

    24.1. USA Neurological Disorder Drugs Market Overview

    24.2. USA Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    24.3. USA Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    24.4. USA Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    25. Canada Neurological Disorder Drugs Market

    25.1. Canada Neurological Disorder Drugs Market Overview

    25.2. Canada Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    25.3. Canada Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    25.4. Canada Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    26. South America Neurological Disorder Drugs Market

    26.1. South America Neurological Disorder Drugs Market Overview

    26.2. South America Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    26.3. South America Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    26.4. South America Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    27. Brazil Neurological Disorder Drugs Market

    27.1. Brazil Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    27.2. Brazil Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    27.3. Brazil Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    28. Middle East Neurological Disorder Drugs Market

    28.1. Middle East Neurological Disorder Drugs Market Overview

    28.2. Middle East Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    28.3. Middle East Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    28.4. Middle East Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    29. Africa Neurological Disorder Drugs Market

    29.1. Africa Neurological Disorder Drugs Market Overview

    29.2. Africa Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    29.3. Africa Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    29.4. Africa Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    30. Neurological Disorder Drugs Market Competitive Landscape And Company Profiles

    30.1. Neurological Disorder Drugs Market Competitive Landscape

    30.2. Neurological Disorder Drugs Market Company Profiles

    30.2.1. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis

    30.2.2. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

    30.2.3. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

    30.2.4. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis

    30.2.5. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis

    31. Neurological Disorder Drugs Market Other Major And Innovative Companies

    31.1. Novartis AG

    31.2. GlaxoSmithKline plc

    31.3. Takeda Pharmaceutical Company Limited

    31.4. Eli Lilly and Company Pvt Ltd

    31.5. Amgen Inc.

    31.6. Boehringer Ingelheim GmbH

    31.7. Novo Nordisk A/S

    31.8. Merck KGaA

    31.9. Teva Pharmaceutical Industries Ltd.

    31.10. Otsuka America Pharmaceutical Inc.

    31.11. Biogen Inc.

    31.12. Bausch Health Companies Inc.

    31.13. Alexion Pharmaceuticals Inc.

    31.14. UCB S.A.

    31.15. Eisai Co. Ltd.

    32. Global Neurological Disorder Drugs Market Competitive Benchmarking And Dashboard

    33. Key Mergers And Acquisitions In The Neurological Disorder Drugs Market

    34. Recent Developments In The Neurological Disorder Drugs Market

    35. Neurological Disorder Drugs Market High Potential Countries, Segments and Strategies

    35.1 Neurological Disorder Drugs Market In 2029 - Countries Offering Most New Opportunities

    35.2 Neurological Disorder Drugs Market In 2029 - Segments Offering Most New Opportunities

    35.3 Neurological Disorder Drugs Market In 2029 - Growth Strategies

    35.3.1 Market Trend Based Strategies

    35.3.2 Competitor Strategies

    36. Appendix

    36.1. Abbreviations

    36.2. Currencies

    36.3. Historic And Forecast Inflation Rates

    36.4. Research Inquiries

    36.5. The Business Research Company

    36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Table 3: Global Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 4: Global Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 5: Global Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 6: Global Neurological Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 7: Global Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 8: Global Neurological Disorder Drugs Market, Sub-Segmentation Of Cholinesterase Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 9: Global Neurological Disorder Drugs Market, Sub-Segmentation Of N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 10: Global Neurological Disorder Drugs Market, Sub-Segmentation Of Antiepileptic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 11: Global Neurological Disorder Drugs Market, Sub-Segmentation Of Antipsychotic and Antidepressant, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 12: Global Neurological Disorder Drugs Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 13: Global Neurological Disorder Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 14: Global Neurological Disorder Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 15: Asia-Pacific, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 16: Asia-Pacific, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 17: Asia-Pacific, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 18: China, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 19: China, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 20: China, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 21: India, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 22: India, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 23: India, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 24: Japan, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 25: Japan, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 26: Japan, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 27: Australia, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 28: Australia, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 29: Australia, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 30: Indonesia, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 31: Indonesia, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 32: Indonesia, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 33: South Korea, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 34: South Korea, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 35: South Korea, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 36: Western Europe, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 37: Western Europe, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 38: Western Europe, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 39: UK, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 40: UK, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 41: UK, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 42: Germany, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 43: Germany, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 44: Germany, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 45: France, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 46: France, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 47: France, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 48: Italy, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 49: Italy, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 50: Italy, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 51: Spain, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 52: Spain, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 53: Spain, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 54: Eastern Europe, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 55: Eastern Europe, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 56: Eastern Europe, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 57: Russia, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 58: Russia, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 59: Russia, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 60: North America, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 61: North America, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 62: North America, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 63: USA, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 64: USA, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 65: USA, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 66: Canada, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 67: Canada, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 68: Canada, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 69: South America, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 70: South America, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 71: South America, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 72: Brazil, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 73: Brazil, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 74: Brazil, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 75: Middle East, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 76: Middle East, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 77: Middle East, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 78: Africa, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 79: Africa, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 80: Africa, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 81: F. Hoffmann-La Roche Ltd Financial Performance
  • Table 82: Bayer AG Financial Performance
  • Table 83: Sanofi S.A. Financial Performance
  • Table 84: AstraZeneca PLC Financial Performance
  • Table 85: Abbott Laboratories Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Figure 3: Global Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 4: Global Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 5: Global Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 6: Global Neurological Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 7: Global Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 8: Global Neurological Disorder Drugs Market, Sub-Segmentation Of Cholinesterase Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 9: Global Neurological Disorder Drugs Market, Sub-Segmentation Of N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 10: Global Neurological Disorder Drugs Market, Sub-Segmentation Of Antiepileptic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 11: Global Neurological Disorder Drugs Market, Sub-Segmentation Of Antipsychotic and Antidepressant, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 12: Global Neurological Disorder Drugs Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 13: Global Neurological Disorder Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 14: Global Neurological Disorder Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 15: Asia-Pacific, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 16: Asia-Pacific, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 17: Asia-Pacific, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 18: China, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 19: China, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 20: China, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 21: India, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 22: India, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 23: India, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 24: Japan, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 25: Japan, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 26: Japan, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 27: Australia, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 28: Australia, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 29: Australia, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 30: Indonesia, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 31: Indonesia, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 32: Indonesia, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 33: South Korea, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 34: South Korea, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 35: South Korea, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 36: Western Europe, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 37: Western Europe, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 38: Western Europe, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 39: UK, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 40: UK, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 41: UK, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 42: Germany, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 43: Germany, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 44: Germany, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 45: France, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 46: France, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 47: France, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 48: Italy, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 49: Italy, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 50: Italy, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 51: Spain, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 52: Spain, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 53: Spain, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 54: Eastern Europe, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 55: Eastern Europe, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 56: Eastern Europe, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 57: Russia, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 58: Russia, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 59: Russia, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 60: North America, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 61: North America, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 62: North America, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 63: USA, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 64: USA, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 65: USA, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 66: Canada, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 67: Canada, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 68: Canada, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 69: South America, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 70: South America, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 71: South America, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 72: Brazil, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 73: Brazil, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 74: Brazil, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 75: Middle East, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 76: Middle East, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 77: Middle East, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 78: Africa, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 79: Africa, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 80: Africa, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 81: F. Hoffmann-La Roche Ltd Financial Performance
  • Figure 82: Bayer AG Financial Performance
  • Figure 83: Sanofi S.A. Financial Performance
  • Figure 84: AstraZeneca PLC Financial Performance
  • Figure 85: Abbott Laboratories Financial Performance

The Business Research Company offers the plasma fractionation market research report 2022 with industry size, share, segments and market growth

Read More

Latest Cell Therapy Market Growth Study 2022-2026 By The Business Research Company

Read More

Global Gene Therapy Market 2022 – Market Opportunities And Strategies

Read More

The Microbiome Market Share, Market Size, And Growth Rate 2022

Read More

Latest TNF Alpha Inhibitors Market Growth Study 2022-2026 By The Business Research Company

Read More

The Business Research Company offers the pancreatic cancer drugs market research report 2022 with industry size, share, segments and market growth

Read More

The Business Research Company offers the fertility drugs market research report 2022 with industry size, share, segments and market growth

Read More

The Business Research Company offers the antivirals market research report 2022 with industry size, share, segments and market growth

Read More

Plasma Powder Global Market Report 2025 – By Source (Bovine, Porcine, Ovine, Other Sources), By Form (Dry, Wet), By Sales Channel (Online, Offline), By Application (Pet Food, Pig Feed, Poultry Feed, Aqua Feed, Ruminant Feed, Human Food, Other Applications) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Magnesium Oxide Nanopowder Global Market Report 2025 – By Type (99% Magnesium Oxide Nanopowder, 99.9% Magnesium Oxide Nanopowder, 99.99% Magnesium Oxide Nanopowder, 99.999% Magnesium Oxide Nanopowder), By Application (Refractory Materials, Electric Insulation, Magnetic Devices, Fuel Additive, Fire Retardant), By End-User Industry (Metallurgy, Construction, Oil And Gas, Automotive, Electrical And Electronics, Other End-User Industries) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Automotive Shielding Global Market Report 2025 – By Shielding Type (Heat Shielding, EMI Shielding), By Material Type (Metallic, Non-Metallic), By Vehicle Type (Passenger Car, Light Commercial Vehicle, Heavy Commercial Vehicle) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Coordinate Measuring Machine Global Market Report 2025 – By Type (Fixed CMM, Portable CMM ), By Application (Inspection, Reverse Engineering), By Industry (Automotive, Aerospace, Heavy Machinery, Energy and Power, Electronics, Medical, Other Industries) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Mining Automation Global Market Report 2025 – By Offering( Equipment, Software, Communication System ), By Technique( Surface Mining, Underground Mining), By Workflow( Mine Development, Mining Process, Mine Maintenance ), By Application( Metal Mining, Mineral Mining, Coal Mining) – Market Size, Trends, And Global Forecast 2025-2034

View Report

RF Signal Chain Components Global Market Report 2025 – By Product (Amplifiers, Voltage-Controlled Oscillators, Power Dividers, Mixers, Filters, Switches, Attenuators, Diplexers, Duplexers, Couplers ), By Material Type (Gallium Arsenide (GaAs), Gallium Nitride (GaN), Silicon (Si), Silicon Germanium (SiGe), Other Materials), By Frequency Band (VHF Or UHF Band, L Band, K Band, Ka Band, V Band, W Band), By Application (Telecom Infrastructure, Consumer Electronics, SATCOM (Satellite Communications), Aerospace And Defense, Automotive, Medical, Other Applications) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Alzheimer's Drugs Global Market Report 2025 – By Drugs (Donepezil, Rivastigmine, Galantamine, Memantine ), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy ), By Application (Early To Moderate Stages, Moderate To Severe Stages) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Aerospace Helmet Mounted Display Global Market Report 2025 – By Component (Processor And Memory, Controller, Sensor, Display, Lens, Other Components ), By Technology (Augmented Reality, Virtual Reality ), By Application (Military, Non-Military), By End User (Astronauts, Aircraft Personnel, Other End User) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Frequently Asked Questions

What is the definition of the Neurological Disorder Drugs market?

Neurological disorder drugs refer to medications used to treat disorders of the nervous system. These disorders can affect the brain, spinal cord, and nerves throughout the body. The drugs aim to manage symptoms, slow the progression of the disorder, and improve the quality of life for individuals affected. For further insights on the Neurological Disorder Drugs market, request a sample here

How will the Neurological Disorder Drugs market drivers and restraints affect the market dynamics? What forces will shape the Neurological Disorder Drugs industry going forward?

The Neurological Disorder Drugs market major growth driver - Rising Neurological Disorders Drive Growth In Drugs Market. For further insights on the Neurological Disorder Drugs market, request a sample here

What is the forecast market size or the forecast market value of the Neurological Disorder Drugs market?

The Neurological Disorder Drugs market size has grown strongly in recent years. The neurological disorder drugs market size has grown strongly in recent years. It will grow from $84.6 billion in 2024 to $90.09 billion in 2025 at a compound annual growth rate (CAGR) of 6.5%. The growth in the historic period can be attributed to increasing animal testing and obtaining promising results, an increase in therapeutic treatments, the growth of neurological problems, government initiatives, and a growth in healthcare expenditure. The neurological disorder drugs market size is expected to see strong growth in the next few years. It will grow to $114.65 billion in 2029 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to expanding therapeutic options and personalized therapies, a growing focus on disease-modifying treatments, the expanding use of digital biomarkers, and the increasing prevalence of neurological diseases. Major trends in the forecast period include advancements in drug design, advancements in neuroimaging, advancements in genetic research, collaborations and licensing agreements, and the emergence of regenerative medicine. For further insights on the Neurological Disorder Drugs market, request a sample here

How is the Neurological Disorder Drugs market segmented?

The neurological disorder drugs market covered in this report is segmented –
1) By Drug Class: Cholinesterase Inhibitors, N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, Antiepileptic, Antipsychotic And Antidepressant, Other Drugs Classes
2) By Indication: Epilepsy, Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Cerebrovascular Disease, Other Indications
3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels
5) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End Users Subsegtments:
1) By Cholinesterase Inhibitors: Donepezil, Rivastigmine, Galantamine
2) By N-Methyl-D-Aspartate (NMDA) Receptor Antagonists: Memantine, Other NMDA Receptor Antagonists
3) By Antiepileptic: Sodium Channel Blockers, GABA Enhancers, Glutamate Modulators, Other Antiepileptics
4) By Antipsychotic and Antidepressant: Risperidone, Olanzapine, SSRIs, SNRIs, Tricyclic
5) By Other Drug Classes: Dopaminergic Drugs, Alpha-2 Agonists, Immunomodulators, Other Neurological Disorder Medications For further insights on the Neurological Disorder Drugs market, request a sample here

Which region has the largest share of the Neurological Disorder Drugs market? What are the other regions covered in the report?

North America was the largest region in the neurological disorder drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurological disorder drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. For further insights on the Neurological Disorder Drugs market, request a sample here.

Who are the major players in the Neurological Disorder Drugs market?

Major companies operating in the neurological disorder drugs market are focusing on developing innovative Ocrelizumab drug therapies to enhance treatment efficacy, improve patient outcomes, and expand therapeutic options for individuals with multiple sclerosis. Ocrelizumab is a humanized monoclonal antibody used as a therapeutic drug in the treatment of multiple sclerosis (MS), a type of neurological disorder. For instance, in February 2024, Roche Holding AG, a Switzerland-based pharmaceutical company, launched Ocrevus (Ocrelizumab), a new disease-modifying therapy (DMT) drug for the treatment of multiple sclerosis in India. Ocrevus is the first and only approved DMT for both relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS), based on over 10 years of clinical and real-world data. It is a monoclonal antibody that targets CD20-positive B cells, which are believed to play a role in the autoimmune attack on the central nervous system in multiple sclerosis (MS). Ocrevus is used to treat both relapsing-remitting MS (RRMS) and primary progressive MS (PPMS), making it the first drug approved for both forms of the disease. It is administered intravenously, typically every six months, and has shown efficacy in reducing disease activity and disability progression in clinical trials.. For further insights on the Neurological Disorder Drugs market, request a sample here.

What are the key trends in the Neurological Disorder Drugs market?

Major trends in the Neurological Disorder Drugs market include Innovative Approaches In Neurological Disorder Drugs Advancing Treatment For Multiple Sclerosis. For further insights on the Neurological Disorder Drugs market, request a sample here.

What are the major opportunities in the Neurological Disorder Drugs market? What are the strategies for the Neurological Disorder Drugs market?

For detailed insights on the major opportunities and strategies in the Neurological Disorder Drugs market, request a sample here.

How does the Neurological Disorder Drugs market relate to the overall economy and other similar markets?

For detailed insights on Neurological Disorder Drugs's relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the Neurological Disorder Drugs industry?

For detailed insights on the mergers and acquisitions in the Neurological Disorder Drugs industry, request a sample here.

What are the key dynamics influencing the Neurological Disorder Drugs market growth? SWOT analysis of the Neurological Disorder Drugs market.

For detailed insights on the key dynamics influencing the Neurological Disorder Drugs market growth and SWOT analysis of the Neurological Disorder Drugs industry, request a sample here.